INTRODUCTION {#s1}
============

Breast cancer is the most common cancer among women worldwide and can be divided into several groups based on molecular analyses. One type is triple-negative breast cancer (TNBC), which comprises 15--20% of all breast cancers \[[@R1]\]. TNBC cells lack expression of the estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor-2. Due to a lack of effective therapy \[[@R1], [@R2]\], progression-free and overall survival rates of TNBC patients are poor \[[@R3]\]. Therefore, a novel effective treatment modality against TNBC is urgently required.

Apoptosis is primarily induced in cancer cells through two major pathways: extrinsic and intrinsic pathways \[[@R4]\]. Fas ligand (FasL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) provide a death signal via the extrinsic apoptotic pathway, activating caspase-8 in cancer cells. In contrast, cytotoxic drugs and high-dose radiation damage DNA and mitochondria, resulting in activation of the intrinsic caspase-9-mediated apoptotic pathway. Although several molecules participate in mitochondria-mediated apoptosis \[[@R5]--[@R7]\], Bcl-2 family members play critical roles in this type of apoptosis \[[@R8], [@R9]\]. The family of Bcl-2-related anti-apoptotic proteins, which includes Bcl-2, Bcl-X~L~, Bcl-w, and Mcl-1, has been shown to contribute to the chemotherapy resistance of several cancer cells \[[@R9]\]. To target members of the Bcl-2 family, several small molecule inhibitors have been developed. ABT-737 and ABT-263 (navitoclax) are small molecule inhibitors of Bcl-2, Bcl-X~L~, and Bcl-w. Several reports have demonstrated the efficacy of these inhibitors against both hematological malignancies and several types of solid tumors \[[@R10]--[@R17]\]. Regardless of the efficacy of these agents, thrombocytopenia due to Bcl-X~L~ inhibition was the major dose-limiting toxicity and was dose-related \[[@R15], [@R18]\]. Alternatively, ABT-199 (venetoclax) is a Bcl-2 inhibitor that spares platelets \[[@R19]\]. ABT-199 is currently one of the most promising agents in clinical development for hematological malignancies \[[@R10]\]. Interestingly, Bcl-2 is commonly associated with ER-positive breast tumors \[[@R20]\] and has been recognized as a favorable prognostic marker in breast cancer \[[@R21], [@R22]\]. In addition, the expression of Bcl-2 predicts the efficacy of adjuvant chemotherapy in breast cancer patients \[[@R23]\]. Furthermore, downregulation of Bcl-2 enhances the effects of chemotherapeutic agents in human breast cancer cells \[[@R24]\]. However, its potential role in TNBC has not yet been fully determined. Given that Bcl-2 is an anti-apoptotic protein, Bcl-2 could be a target molecule in the treatment of TNBC patients.

Current chemotherapy treatment for breast cancer consists of anthracycline and cyclophosphamide in combination with taxanes \[[@R25]\]. Because doxorubicin (DR), an anthracycline agent, has frequently been used in the treatment of breast cancer, it is therapeutically important to search for modalities that can enhance DR-induced antitumor effects in TNBC. In addition, patients with Bcl-2-negative TNBC were suggested to benefit from chemotherapy, including DR \[[@R26]\]. To this end, in this study, we determined whether the Bcl-2 inhibitor ABT-199 could augment the DR-induced antitumor effects in two TNBC cell lines, MDA-MB-231 and BT-549. Our results indicate that ABT-199 can enhance DR-induced antitumor effects: induction of apoptosis and inhibition of the colony-forming ability of TNBC cells. Furthermore, ABT-199 enhanced DR-induced growth suppression of MDA-MB-231 cells in a xenograft mouse model. These results reveal that Bcl-2 inhibition can potentiate the antitumor effects of DR in TNBC.

RESULTS {#s2}
=======

Combination treatment with DR and ABT-199 decreased the viability of TNBC cells {#s2_1}
-------------------------------------------------------------------------------

We first examined the effects of DR and ABT-199 in two TNBC cell lines. DR decreased cell viability in a dose-dependent manner (Figure [1A](#F1){ref-type="fig"}). BT-549 cells were more sensitive to DR than MDA-MB-231 cells, whereas MDA-MB-231 cells were more sensitive to ABT-199 than BT-549 cells (Figure [1B](#F1){ref-type="fig"}). When cells were treated with both DR and ABT-199, viability was decreased even further compared with either treatment alone (Figure [1C](#F1){ref-type="fig"}). Representative results are shown in Figure [1D](#F1){ref-type="fig"} (*p*\<0.01; control group versus the other groups). These results indicate that the combination of DR and ABT-199 can effectively decrease the viability of TNBC cells *in vitro*.

![Cell viability of triple-negative breast cancer (TNBC) cells treated with doxorubicin (DR) and/or ABT-199\
**(A)** TNBC cells were cultured with the indicated doses of DR (nM) for 48 h. **(B)** TNBC cells were cultured with the indicated doses of ABT-199 (μM) for 48 h. **(C)** TNBC cells were cultured with the indicated doses of DR (nM) and/or ABT-199 (μM) for 48 h. In these experiments, cell viability (%) was determined using the WST-8 assay. The results are shown as the means ± standard deviation (SD) of three wells. Similar results were obtained in four separate experiments. **(D)** Representative results (MDA-MB-231 cells, 500 nM DR and 15 μM ABT-199; and BT-549 cells, 50 nM DR and 20 μM ABT-199) are shown. ^\*\*^*p* \< 0.01.](oncotarget-09-25545-g001){#F1}

Combination treatment with DR and ABT-199 triggered caspase-dependent apoptosis in TNBC cells {#s2_2}
---------------------------------------------------------------------------------------------

Microscopic observation of MDA-MB-231 cells revealed that DR treatment increased cell size and treatment with both DR and ABT-199 resulted in a drastic destruction of MDA-MB-231 cells (Figure [2A](#F2){ref-type="fig"}). Therefore, we performed an apoptosis assay following annexin V-fluorescein isothiocyanate (FITC) and propidium iodide (PI) staining. As shown in Figure [2B](#F2){ref-type="fig"}, although treatment with DR or ABT-199 alone slightly increased the percentage of annexin V-positive MDA-MB-231 cells, combination treatment with DR and ABT-199 drastically increased the percentage of annexin V-positive cells. Unexpectedly, DR treatment increased the longitudinal FL2 intensity of MDA-MB-231 cells likely because PI emitted red fluorescence. Combination treatment with DR and ABT-199 increased the percentage of annexin V-positive BT-549 cells, whereas the induction of apoptosis was not as marked in MDA-MB-231 cells (Figure [2C](#F2){ref-type="fig"}). PI staining slightly increased the FL2 intensity.

![Apoptosis in TNBC cells following combination treatment with DR and ABT-199\
**(A)** MDA-MB-231 cells were treated with 10 μM ABT-199 and/or 500 nM DR. After 2 days, images were obtained. **(B)** MDA-MB-231 cells were treated with 10 μM ABT-199 and/or 500 nM DR. After 2 days, cells were stained with fluorescein isothiocyanate (FITC)-conjugated annexin V and propidium iodide (PI), and flow cytometry was performed. **(C)** Similarly, BT-549 cells were treated with 20 μM ABT-199 and/or 25 nM DR, and cells were analyzed by flow cytometry. The numbers represent the percentages of annexin V-positive cells.](oncotarget-09-25545-g002){#F2}

We next determined whether cell death induced by the combination of DR and ABT-199 was due to caspase-dependent apoptosis. Although the inhibitory efficacy was only partial, the addition of the pan-caspase inhibitor, z-VAD, decreased the percentages of annexin V-positive cells in both cell lines treated with DR and ABT-199 (Figure [3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}) (*p*\<0.01; z-VAD versus DMSO). Additionally, immunoblotting revealed that the combination treatment increased the cleavage of caspase-3, -8, and -9 in both cell lines (Figure [3C](#F3){ref-type="fig"}), indicating that the combination of DR and ABT-199 induces caspase-dependent apoptosis of TNBC cells, at least partially.

![Caspase-dependent apoptosis in TNBC cells treated with DR and ABT-199\
**(A)** TNBC cells were treated with both DR and ABT-199 for 48 h (MDA-MB-231 cells, 500 nM DR and 10 μM ABT-199; and BT-549 cells, 25 nM DR and 20 μM ABT-199). In some groups, 20 μM z-VAD or dimethyl sulfoxide (DMSO), as a vehicle control, was added. After staining with FITC-conjugated annexin V/PI, the cells were analyzed by flow cytometry. The numbers represent the percentages of annexin V-positive cells. **(B)** The results are shown as the means ± SD of three wells. ^\*\*^*p* \< 0.01. **(C)** TNBC cells were treated with ABT-199 and/or DR at the doses described above. After 24 h, cells were harvested and examined for their expression of caspase-3, -8, and -9 by immunoblotting. α-Tubulin was used as a control.](oncotarget-09-25545-g003){#F3}

Genetic knockdown of Bcl-2 increased the sensitivity of TNBC cells to DR {#s2_3}
------------------------------------------------------------------------

The treatment with ABT-199 showed no effect on the protein expression of Bcl-2 in two TNBC cell lines *in vitro* ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). Therefore, we next determined whether genetic knockdown of Bcl-2 could sensitize TNBC cells to DR. Both cell lines were positive for Bcl-2 at the protein level, and transfection with Bcl-2-targeted short interfering RNA (siRNA) decreased the expression of Bcl-2 (Figure [4A](#F4){ref-type="fig"}). Knockdown of Bcl-2 showed no definite effect on the expression of Bcl-X~S/L~ and Mcl-1. Bcl-2 knockdown in MDA-MB-231 cells significantly increased the percentage of annexin V-positive DR-treated cells compared with control siRNA-transfected and DR-treated cells (Figure [4B](#F4){ref-type="fig"} and [4C](#F4){ref-type="fig"}) (*p*\<0.01). Although no difference in the percentage of annexin V-positive cells was observed between control siRNA-transfected untreated BT-549 cells and control siRNA-transfected DR-treated BT-549 cells, Bcl-2 knockdown significantly increased the sensitivity of BT-549 cells to DR (*p*\<0.05).

![Genetic knockdown of Bcl-2 increased the sensitivity of TNBC cells to DR\
**(A)** TNBC cells were transfected with Bcl-2 short interfering RNA (siRNA) or control siRNA. After 2 days, cells were harvested and examined for expression of Bcl-2, Bcl-X, and Mcl-1. α-Tubulin was used as a control. **(B)** Two days after siRNA transfection, MDA-MB-231 and BT-549 cells were cultured with 500 and 25 nM DR, respectively, for 48 h. Following staining with FITC-conjugated annexin V/PI, flow cytometry was performed. The numbers represent the percentages of annexin V-positive cells. **(C)** The results are shown as the means ± SD of three wells. ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01. NS, not significant.](oncotarget-09-25545-g004){#F4}

Combination treatment with DR and ABT-199 decreased the colony-forming ability of TNBC cells {#s2_4}
--------------------------------------------------------------------------------------------

We next examined the effect of combination treatment with DR and ABT-199 on the colony-forming ability of TNBC cells. Although higher doses of DR (500 and 25 nM for MDA-MB-231 and BT-549 cells, respectively) were used in the apoptosis assay (Figure [2](#F2){ref-type="fig"}), 2-day treatment at such doses drastically abolished the colony-forming ability (data not shown). Therefore, based on the results of dose titration experiments, MDA-MB-231 and BT-549 cells were treated with 3 and 2 nM DR, respectively. Although treatment with DR alone decreased colony numbers in both cell lines to some degree, the combination treatment significantly suppressed the colony-forming ability of both cell lines more profoundly (Figure [5A](#F5){ref-type="fig"}) (*p*\<0.01; combination group versus ABT-199 group and *p*\<0.05; combination group versus the DR group). Representative results are shown in Figure [5B](#F5){ref-type="fig"}. This suppression was more apparent in MDA-MB-231 cells compared with BT-549 cells. These results indicate that combination treatment with DR and ABT-199 can exert antitumor effects on TNBC cells via inhibition of their colony-forming ability.

![Combination treatment with DR and ABT-199 impaired the colony-forming ability of TNBC cells\
**(A)** TNBC cells were cultured with the indicated doses of DR and/or ABT-199 (MDA-MB-231 cells, 3 nM DR and 20 μM ABT-199; and BT-549 cells, 2 nM DR and 20 μM ABT-199). After 2 days, the supernatant was replaced with new culture medium without reagents and cultured for an additional 7 or 10 days. Colonies were counted after staining with 0.05% crystal violet. The results are shown as the means ± SD of three wells. ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01. **(B)** Representative results are shown.](oncotarget-09-25545-g005){#F5}

Combination therapy with DR and ABT-199 suppressed the tumor growth of MDA-MB-231 cells *in vivo* {#s2_5}
-------------------------------------------------------------------------------------------------

Finally, we determined whether combination treatment with DR and ABT-199 could exert an antitumor effect against subcutaneously established MDA-MB-231 cells using a xenograft mouse model. Nude mice were subcutaneously inoculated with MDA-MB-231 cells into the right flank and divided into four groups on day 20. ABT-199 (50 mg/kg) was administered orally on days 21, 22, 23, 24, 25, and 26. DR (100 μg/50 μl) was injected intratumorally on days 22 and 24 (Figure [6A](#F6){ref-type="fig"}). Although treatment with ABT-199 alone failed to show tumor suppression and the injection of DR alone suppressed tumor growth on days 34 and 40 compared with the untreated control (*p* \< 0.05), the combination of DR and ABT-199 significantly suppressed tumor growth (p \< 0.01 versus control group) (Figure [6B](#F6){ref-type="fig"}). In terms of body weight, although the combination therapy transiently decreased body weight, it recovered soon after (Figure [6C](#F6){ref-type="fig"}). These results indicate that combination therapy with DR and ABT-199 can inhibit the tumor growth of human TNBC cells *in vivo*.

![Combination treatment with DR and ABT-199 suppressed the growth of MDA-MB-231 cells *in vivo*\
**(A)** Experimental protocol. **(B)** (Left) Tumor growth of MDA-MB-231 cells is shown. Each group consists of six BALB *nu/nu* mice. (Right) Tumor size, product of two perpendicular diameters, was measured every 3 or 4 days. The results are shown as the means ± SD of six mice. ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.01 (ANOVA). **(C)** Body weight was measured every 3 or 4 days. The results are shown as the means ± SD of six mice. NS, not significant.](oncotarget-09-25545-g006){#F6}

DISCUSSION {#s3}
==========

In this study, we investigated the therapeutic effect of combining the genotoxic drug DR and the Bcl-2 inhibitor ABT-199 in two human TNBC cell lines and revealed that ABT-199 could effectively enhance the susceptibility of TNBC cells to DR.

DR is a frequently used cytotoxic drug for the treatment of breast cancer. However, since TNBC is generally refractory to current anti-cancer therapies, including DR, an efficient treatment modality has been urgently required. Bcl-2 family members play multiple roles in apoptosis. ABT-199 is a Bcl-2 specific inhibitor that can be administered orally \[[@R18]\]. Other Bcl-2 family inhibitors, such as ABT-737 and ABT-263, inhibit not only Bcl-2 but also Bcl-X~L~ and Bcl-w \[[@R27]\]. We previously reported that ABT-737 and ABT-263 could sensitize human prostate cancer cells and pancreatic cancer cells to docetaxel and TRAIL, respectively \[[@R28], [@R29]\]. However, Bcl-X~L~ is important in the survival of platelets, and a gradual reduction of Bcl-X~L~ results in apoptosis of senescent platelets \[[@R30]\]. Therefore, in a clinical trial of ABT-263 (navitoclax), it was shown that doses of ABT-263 must be reduced to avoid severe thrombocytopenia \[[@R15], [@R17]\]. In contrast, in a phase II study of ABT-199 monotherapy for patients with acute myelogenous leukemia, common adverse events did not include severe thrombocytopenia \[[@R31]\]. Based on these lines of evidence, we tested the ability of the Bcl-2 inhibitor ABT-199 to augment the antitumor effects of DR on TNBC.

Cytotoxic chemotherapeutic drugs generally induce mitochondria-mediated apoptosis. Overexpression of Bcl-2 proteins can induce drug resistance in many types of epithelial cancer cells because Bcl-2 decreases mitochondrial apoptosis by stabilizing mitochondrial permeability \[[@R32]\]. Bcl-2 proteins inhibit the release of cytochrome c from mitochondria into the cytosol to activate caspase-3 and -9. In this study, we showed that combination treatment with DR and ABT-199 induced caspase-dependent apoptosis in TNBC cells. Using immunoblotting, we showed that this combination treatment induced cleavage of both caspase-8 and -9 (Figure [3C](#F3){ref-type="fig"}). In general, cytotoxic drugs, including DR, damage DNA and mitochondria, resulting in activation of intrinsic caspase-9-mediated apoptosis. Bcl-2 family members play a critical role in this type of apoptosis \[[@R8], [@R9]\], whereas the extrinsic apoptotic pathway, which can be induced by FasL and TRAIL, activates caspase-8. Interestingly, drug-induced endoplasmic reticulum stress can induce apoptosis in cancer cells via death receptor-mediated activation of caspase-8 \[[@R33]\]. In reverse, activation of caspase-8 can trigger intrinsic caspase-9-mediated apoptosis through truncation of Bid \[[@R34], [@R35]\]. In general, the induction of apoptosis can involve both pathways.

Mutation or loss of the *p53* gene is frequently observed in many types of human cancers and is associated with poor prognosis and chemoresistance \[[@R36], [@R37]\]. Chemotherapy-induced killing of cancer cells requires activation of BH3-only proteins, such as PUMA and NOXA, by upstream signaling mediators including p53 \[[@R38]\]. These upstream signal activators are frequently mutated, lost, or silenced during tumor development or during emergence of therapy-resistant cancer cells \[[@R38]\]. To overcome such resistance, a new class of therapeutics, known as BH3-mimetics such as ABT-199, has been developed \[[@R38]\]. In this study, we used two human TNBC cell lines, MDA-MB-231 and BT-549, both of which carry a mutation in the *p53* gene \[[@R39]\]. Our results suggest that combination treatment with DR and ABT-199 is effective even against breast cancers with a mutant *p53* gene.

Although tumors expressing high levels of Bcl-2 respond effectively to the Bcl-2 family inhibitor ABT-737 in combination with docetaxel, tumors expressing low levels of Bcl-2 showed no response \[[@R40]\]. Additionally, ABT-737 monotherapy has been shown to be effective in treating some malignancies, including follicular lymphoma and chronic lymphocytic leukemia \[[@R27]\], whereas this inhibitor was not effective against breast tumors in xenograft models \[[@R40]\]. These data suggest that Bcl-2 inhibition is effective against lymphoid malignancies in which Bcl-2 is a key oncogenic driver \[[@R41]\], but that this inhibition alone is not as effective in the treatment of breast cancer. However, as shown in this study, Bcl-2 inhibition can effectively sensitize TNBC cells to the cytotoxic drug DR. Given that Bcl-2 is overexpressed in approximately 75% of breast cancers \[[@R22]\], this combination therapy appears promising.

It has been reported that targeting Bcl-2 with ABT-199 can increase therapeutic effects of tamoxifen on ER^+^ breast cancer in primary breast tumor xenograft models \[[@R14]\]. In addition, *in vivo* silencing of Bcl-2 with nanoliposomal Bcl-2 siRNA can inhibit the growth of xenografted ER^-^ and ER^+^ breast cancers \[[@R42]\]. In this study, combination treatment with DR and ABT-199 was effective in a xenograft model of triple-negative MDA-MB-231 cells, compared with either therapy alone (Figure [6](#F6){ref-type="fig"}). Although transient body weight loss was observed in mice following combination therapy, this adverse event was soon recovered. These lines of *in vivo* evidence suggest that Bcl-2 is a promising target in treating not only ER^+^ breast cancer but also TNBC.

Overall, we investigated the sensitizing effect of the Bcl-2 inhibitor ABT-199 on DR-induced antitumor effects in two TNBC cell lines. Our data indicate that ABT-199 effectively enhanced DR-induced anti-tumor effects both *in vitro* and *in vivo*. Given that the emergence of DR-resistance in patients with TNBC has been an important therapeutic hurdle, our findings provide a clue to overcome DR resistance. Finally, our results suggest that determining the expression of Bcl-2 may identify a subset of TNBC patients who may benefit from treatment with the Bcl-2 inhibitor ABT-199.

MATERIALS AND METHODS {#s4}
=====================

Cell culture and reagents {#s4_1}
-------------------------

Two human breast cancer cell lines (MDA-MB-231 and BT-549), which were kindly provided by Dr. K. Takenaga (Shimane University Faculty of Medicine), were maintained in DMEM medium (Sigma-Aldrich, St. Louis, MO) supplemented with 10% FCS (Invitrogen, Grand Island, NY) and 20 μg/ml gentamicin (Sigma-Aldrich) at 37°C in a humidified atmosphere with 5% CO~2~. ABT-199 was purchased from Chemie Tek (Indianapolis, IN, USA). DR was obtained from Sigma-Aldrich and diluted at first in dH2O and subsequently in PBS. The pan-caspase inhibitor z-VAD-FMK was purchased form Enzo Life Science (Farmingdale, NY, USA).

Cell viability assay {#s4_2}
--------------------

Cell viability was measured using the 2-(2-methoxy-4 -nitrophenyl)-3-(4-nitrophenyl)-5-(2, 4-disulfophenyl)-2H-tetrazolium monosodium salt (WST-8) assay (Nacalai Tesque, Kyoto, Japan). Briefly, cells were seeded in flat-bottomed 96-well plates and doxorubicin and/or ABT-199 at the indicated doses was added. Two days later, 10 μl WST-8 solution was added to each well and the plates were incubated for an additional 3 h. The plates were read at a wavelength of 450 nm using a microplate reader (Beckman Counter, Brea, CA, USA).

Photograph {#s4_3}
----------

Cancer cells were treated with ABT-199 and/or DR. After two days, photograph was taken using IX71, DP12, and TH4-100 (Olympus, Tokyo, Japan).

Flow cytometric analysis {#s4_4}
------------------------

Apoptosis was measured using the annexin V-FITC Apoptosis Detection Kit (BioVision, Mountain View, CA) and propidium iodide (PI). Analysis was performed using a FACS Calibur flow cytometer (Becton Dickinson, Fullerton, CA). For inhibition assays, pan caspase inhibitor z-VAD-FMK (20 μM) was added at the initiation of culture. DMSO was used as a vehicle control.

Immunoblot assay {#s4_5}
----------------

Cells were lysed with the M-PER mammalian protein extraction reagent (Thermo Scientific, Rockford, IL) containing a protease inhibitor cocktail (Nacalai Tesque). Equal amounts of protein were resolved on 4--12% gradient or 12% SDS-PAGE gels, followed by transfer to polyvinylidene fluoride membranes. After blocking membranes, blots were incubated with the indicated primary antibodies: anti-Bcl-2 (sc-492; Santa cruz biotechnology \[SCB\], Dallas, Texas, USA, anti-Bcl-X~S/L~ (\#633901; BioLegend, San Diego, CA, USA ), anti-Mcl-1 (sc-819; SCB ), anti-caspase-3 (9668; Cell Signaling Technology \[CST\], Danvers, MA, USA ), anti-caspase-8 (M032-3; Medical and Biological Laboratories, Nagoya, Japan), anti-caspase-9 (9508; CST), anti-β-actin (BioLegend ) or anti-α-tubulin (SCB). After washing, room temperature incubation of membranes for 30 min with either goat anti-rabbit or goat anti-mouse alkaline phosphatase-conjugated secondary antibodies (Invitrogen) were used to detect the primary antibodies. Protein bands were visualized using an ImageQuant LAS-4000 system (FujiFilm, Tokyo, Japan).

Transfection of siRNA {#s4_6}
---------------------

Transfection of siRNA was performed using Lipofectamine™ RNAiMAX (Invitrogen, Grand Island, NY, USA) according to the manufacturer's instructions. siRNAs targeting Bcl-2 were purchased from SCB and Invitrogen, respectively. Control siRNA (\#6568) was purchased from CST. The transfected cells were used for the experiments 2 days after siRNA transfection.

Colony-forming assay {#s4_7}
--------------------

Cells were seeded in flat-bottomed six-well plates with DR and/or ABT-199 at the indicated doses. Two days later, the medium was replaced with new medium without reagents, and the culture was continued for additional 9-12 days. Thereafter, colonies were fixated with methanol and stained with 0.05% crystal violet, then counted.

*In vivo* xenograft model {#s4_8}
-------------------------

BALB *nu/nu* female mice, purchased from CLEA Japan Inc. (Tokyo, Japan), were maintained under specific pathogen-free conditions. The protocol was approved by Committee on the Ethics of Animal Experiments of the Shimane University Faculty of Medicine (Permit Number: IZ26-107, IZ29-50). All efforts were made to minimize suffering. Mice were inoculated subcutaneously into the right flank with MDA-MB-231 (5×10^6^ cells) and Matrigel (Japan BD Biosciences, Tokyo, Japan) at a 1:1 volume ratio as a total volume of 100 μl. When the tumor diameter reached approximately 5 mm, the mice were pooled and divided into four groups on day 20. On the indicated days, these MDA-MB-231- bearing mice were treated with DR and/or ABT-199. As a vehicle control for DR, 100 μl PBS was injected intratumorally. As a vehicle control for ABT-199, 100 μl DMSO were orally administered using gavage. The tumor size and product of the two perpendicular diameters were measured twice weekly. Each group contained six mice.

Statistical analysis {#s4_9}
--------------------

Data were statistically evaluated using unpaired two-tailed Student's *t-*tests or an ANOVA together with Tukey's test. A *p*-value less than 0.05 was considered to be statistically significant.

SUPPLEMENTARY MATERIALS FIGURE {#s5}
==============================
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